DE69029937D1 - FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER - Google Patents

FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER

Info

Publication number
DE69029937D1
DE69029937D1 DE69029937T DE69029937T DE69029937D1 DE 69029937 D1 DE69029937 D1 DE 69029937D1 DE 69029937 T DE69029937 T DE 69029937T DE 69029937 T DE69029937 T DE 69029937T DE 69029937 D1 DE69029937 D1 DE 69029937D1
Authority
DE
Germany
Prior art keywords
hiv
binding domain
specific antibodies
epitope
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69029937T
Other languages
English (en)
Other versions
DE69029937T2 (de
Inventor
William Sun
Cecily Sun
Michael Fung
Nancy Chang
Tse-Wen Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Application granted granted Critical
Publication of DE69029937D1 publication Critical patent/DE69029937D1/de
Publication of DE69029937T2 publication Critical patent/DE69029937T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69029937T 1989-04-25 1990-04-25 FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER Expired - Fee Related DE69029937T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34295089A 1989-04-25 1989-04-25
PCT/US1990/002261 WO1990012868A1 (en) 1989-04-25 1990-04-25 Antibodies specific for cd4-binding domain of hiv

Publications (2)

Publication Number Publication Date
DE69029937D1 true DE69029937D1 (de) 1997-03-27
DE69029937T2 DE69029937T2 (de) 1997-05-28

Family

ID=23344000

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69029937T Expired - Fee Related DE69029937T2 (de) 1989-04-25 1990-04-25 FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER

Country Status (9)

Country Link
EP (1) EP0470184B1 (de)
JP (1) JPH0768276B2 (de)
AT (1) ATE148918T1 (de)
AU (1) AU633570B2 (de)
CA (1) CA2051107A1 (de)
DE (1) DE69029937T2 (de)
DK (1) DK0470184T3 (de)
ES (1) ES2097759T3 (de)
WO (1) WO1990012868A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
WO1991010722A2 (en) * 1989-12-27 1991-07-25 Centocor, Inc. Chimeric immunoglobulin for cd4 receptors
AU7217891A (en) * 1990-02-13 1991-09-03 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
JPH05262662A (ja) * 1991-07-15 1993-10-12 Calpis Food Ind Co Ltd:The Ｈｉｖ重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法
US5558865A (en) * 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
DE69304899T2 (de) * 1992-03-06 1997-03-13 Creagen, Inc., Cambridge, Mass. Pathogen-gerichtete biokatalisatoren
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
CA2181590C (en) * 1994-01-19 2009-01-06 Frank A. Robey Peptomers with enhanced immunogenicity
US5618922A (en) * 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
JP2933159B2 (ja) * 1996-03-18 1999-08-09 株式会社椿本チエイン 直線作動機のリミットスイッチ取付構造
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
EP2638072A4 (de) * 2010-11-12 2014-05-07 Univ Rockefeller Fusionsproteine für hiv-therapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
ATE151638T1 (de) * 1987-02-20 1997-05-15 Genentech Inc Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
CA1339857C (en) * 1987-05-29 1998-05-05 Cecily Rou-Yun Sun Monoclonal antibodies to gp120 which neutraleze hiv-1
EP0339504A3 (de) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
CA2066607A1 (en) * 1989-09-22 1991-03-23 Thomas Kieber-Emmons Peptides associated with the cd4 binding region of gp120 and their methods of use

Also Published As

Publication number Publication date
WO1990012868A1 (en) 1990-11-01
EP0470184B1 (de) 1997-02-12
ES2097759T3 (es) 1997-04-16
EP0470184A4 (en) 1992-10-07
ATE148918T1 (de) 1997-02-15
AU5553690A (en) 1990-11-16
DE69029937T2 (de) 1997-05-28
JPH04506004A (ja) 1992-10-22
AU633570B2 (en) 1993-02-04
EP0470184A1 (de) 1992-02-12
JPH0768276B2 (ja) 1995-07-26
CA2051107A1 (en) 1990-10-26
DK0470184T3 (da) 1997-03-10

Similar Documents

Publication Publication Date Title
DE69029937D1 (de) FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
BR9305435A (pt) Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
DK0699077T3 (da) Immunogele HIV-komplekser
EA200300336A1 (ru) Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
DE3853779D1 (de) Hiv-1 neutralisierende monoklonale antikörper.
HK1044778A1 (en) Hiv-peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv hiv
ES2011334A6 (es) Metodo para la deteccion de anticuerpos de hiv-2.
HUP0204250A1 (hu) HIV-protein vagy- polinukleotid alkalmazása vakcina előállítására
SE9102975L (sv) Bakterofag och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
WO1991004273A3 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
CA2170034A1 (en) Recombinant humanized anti-human immunodeficiency virus antibody
BRPI9709524B8 (pt) processo para a produção de um anticorpo para células t que expressam cd4
ATE159983T1 (de) Monoklonaler antikörper gegen htlv-iii (stamm mn)
ES2195200T3 (es) Construccion de peptidos de rama multiples.
SE8701765D0 (sv) Analysis method and means therefor
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
DK0569428T3 (da) Fremgangsmåde til diagnosticering in vitro af HIV-1-virusinfektioner
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
WO1995007465A3 (en) USE OF ANTIBODIES AGAINST β-2 MICROGLOBULIN-FREE, CLASS I HLA MOLECULES TO PROVIDE HIV DIAGNOSTIC TESTS AS WELL AS COMPOSITIONS HAVING A PROTECTIVE ACTION AGAINST HIV INFECTIONS
KR910001032A (ko) Hiv-2 변이체
ATE137801T1 (de) Gegen hiv 1 gp48 spezifische antikörper
Broliden The specificity and function of HIV antibody response.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee